Hepatitis B and C in individuals with a history of antipsychotic medication use: A population-based evaluation.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
08
09
2022
accepted:
28
03
2023
medline:
18
4
2023
entrez:
14
4
2023
pubmed:
15
4
2023
Statut:
epublish
Résumé
A better understanding of links between mental illness and risk of bloodborne infectious disease could inform preventive and therapeutic strategies in individuals with mental illness. We performed a cross-sectional study using the National Health and Nutrition Examination Survey (NHANES) to estimate the seroprevalence of hepatitis B and C in individuals with and without a prior prescription for antipsychotic medications, and to determine whether differences in seroprevalence could be explained by differential distribution in known infection risk factors. Multivariable logistic regression models were used to examine the association between receipt of antipsychotic medication and HBV and HCV seropositivity. Those who had HBV core antibody had 1.64 (95% CI: 0.89, 3.02) times the odds and those with HCV antibody (anti-HCV) had 3.48 (95% CI: 1.71, 7.09) times the odds of having a prescription for at least one antipsychotic medication compared to those who did not have HBV core antibody or HCV antibody, respectively. While prior antipsychotic receipt was a potent risk marker for HCV seropositivity, risk was explained by adjusting for known bloodborne infection risk factors (adjusted ORs 1.01 [95% CI: 0.50, 2.02] and 1.38 [95% CI: 0.44, 4.36] for HBV and HCV, respectively). Prior receipt of antipsychotic medications is a strong predictor of HCV (and to a lesser extent HBV) seropositivity. Treatment with antipsychotic medications should be considered as additional risk markers for individuals who may benefit from targeted prevention, screening, and harm reduction interventions for HCV.
Sections du résumé
BACKGROUND
A better understanding of links between mental illness and risk of bloodborne infectious disease could inform preventive and therapeutic strategies in individuals with mental illness.
METHODS
We performed a cross-sectional study using the National Health and Nutrition Examination Survey (NHANES) to estimate the seroprevalence of hepatitis B and C in individuals with and without a prior prescription for antipsychotic medications, and to determine whether differences in seroprevalence could be explained by differential distribution in known infection risk factors. Multivariable logistic regression models were used to examine the association between receipt of antipsychotic medication and HBV and HCV seropositivity.
RESULTS
Those who had HBV core antibody had 1.64 (95% CI: 0.89, 3.02) times the odds and those with HCV antibody (anti-HCV) had 3.48 (95% CI: 1.71, 7.09) times the odds of having a prescription for at least one antipsychotic medication compared to those who did not have HBV core antibody or HCV antibody, respectively. While prior antipsychotic receipt was a potent risk marker for HCV seropositivity, risk was explained by adjusting for known bloodborne infection risk factors (adjusted ORs 1.01 [95% CI: 0.50, 2.02] and 1.38 [95% CI: 0.44, 4.36] for HBV and HCV, respectively).
CONCLUSIONS
Prior receipt of antipsychotic medications is a strong predictor of HCV (and to a lesser extent HBV) seropositivity. Treatment with antipsychotic medications should be considered as additional risk markers for individuals who may benefit from targeted prevention, screening, and harm reduction interventions for HCV.
Identifiants
pubmed: 37058469
doi: 10.1371/journal.pone.0284323
pii: PONE-D-22-25077
pmc: PMC10104286
doi:
Substances chimiques
Antipsychotic Agents
0
Hepatitis C Antibodies
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0284323Informations de copyright
Copyright: © 2023 Awan et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Am J Psychiatry. 1991 Sep;148(9):1225-30
pubmed: 1883002
Br Med Bull. 2005 Jun 09;73-74:1-15
pubmed: 15947217
Vital Health Stat 2. 2014 Mar;(162):1-33
pubmed: 25569458
Psychol Med. 2013 Jun;43(6):1127-32
pubmed: 22975198
Clin Psychol Rev. 1997;17(3):259-69
pubmed: 9160176
Bull World Health Organ. 1999;77(10):801-7
pubmed: 10593027
Curr HIV/AIDS Rep. 2004 Dec;1(4):186-92
pubmed: 16091241
Aust N Z J Public Health. 2007 Dec;31(6):562-6
pubmed: 18081578
BMC Fam Pract. 2013 May 04;14:55
pubmed: 23641784
Am J Public Health. 2001 Jan;91(1):31-7
pubmed: 11189820
Lancet. 2017 Sep 16;390(10100):1260-1344
pubmed: 28919118
BMC Psychiatry. 2020 Oct 1;20(1):483
pubmed: 33004022
CMAJ. 2005 Jun 21;172(13):1703-11
pubmed: 15967975
Psychiatr Serv. 1998 Oct;49(10):1269
pubmed: 9779893
CNS Spectr. 2019 Jun;24(3):287-312
pubmed: 30295215
Psychiatr Serv. 2004 Nov;55(11):1250-7
pubmed: 15534013
MMWR Recomm Rep. 2020 Apr 10;69(2):1-17
pubmed: 32271723
Lancet Psychiatry. 2016 Jan;3(1):40-48
pubmed: 26620388
BMC Gastroenterol. 2013 May 14;13:86
pubmed: 23672254
Lancet Psychiatry. 2017 Sep;4(9):685-693
pubmed: 28687481
Lancet Psychiatry. 2017 Sep;4(9):651-653
pubmed: 28687480